Matthew Germinaro

机构：Johnson & Johnson (United States), Johnson Research & Development (United States)

发表论文 96 篇 · 总被引 1865 次 · h-index 16

代表论文

• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 104)
• 759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY (2024 · Gastroenterology · 被引 14)
• OP10 Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study (2025 · Journal of Crohn s and Colitis · 被引 13)
• Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease (2024 · Value in Health · 被引 10)
• Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 8)
• Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis (2026 · BMJ Open Gastroenterology · 被引 2)